Haematologica, Vol 92, Issue 3, 414-417 doi:10.3324/haematol.10570
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.-J.
Right arrow Articles by Han, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.-J.
Right arrow Articles by Han, W.

Stem Cell Transplantation

Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation

Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Huan Chen, Wei Han

From the Institute of Hematology, People’s Hospital, Peking University, Beijing, PR China 100044

Correspondence: Xiao-Jun Huang, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, 100044, China E-mail: xjhrm{at}medmail.com.cn

In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after haploidentical hematopoietic stem cell transplantation (HSCT). Twenty patients received DLI at a median of 177 days after HSCT. Eight patients survived in complete remission for a median of 1118 days. The 2-year probability of leukemia-free survival was 40%. Acute graft-versus-host disease (GVHD) grade 3–4 occurred in six patients after DLI. GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT.

Key words: donor lymphocyte infusion, relapse, haploidentical, transplantation.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Xiao-Jun, X. Lan-Ping, L. Kai-Yan, L. Dai-Hong, W. Yu, C. Huan, C. Yu-Hong, H. Wei, W. Jing-Zhi, C. Yao, et al.
Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies
Clin. Cancer Res., July 15, 2009; 15(14): 4777 - 4783.
[Abstract] [Full Text] [PDF]